VCC Stock Overview
Does not have significant operations. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Fresh Tracks Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.73 |
| 52 Week High | US$0.96 |
| 52 Week Low | US$0.44 |
| Beta | 0.49 |
| 11 Month Change | 0% |
| 3 Month Change | -1.48% |
| 1 Year Change | 5.04% |
| 33 Year Change | -98.45% |
| 5 Year Change | n/a |
| Change since IPO | -99.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| VCC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | 0.8% |
| 1Y | 5.0% | -18.3% | 8.6% |
Return vs Industry: VCC underperformed the German Biotechs industry which returned 23.4% over the past year.
Return vs Market: VCC underperformed the German Market which returned 6.2% over the past year.
Price Volatility
| VCC volatility | |
|---|---|
| VCC Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VCC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VCC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 13 | Bert Marchio | ir.frtx.com |
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors. Fresh Tracks Therapeutics, Inc. has license and collaboration agreements with Carna Biosciences, Inc., and Voronoi Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022.
Fresh Tracks Therapeutics, Inc. Fundamentals Summary
| VCC fundamental statistics | |
|---|---|
| Market cap | €4.95m |
| Earnings (TTM) | -€5.24m |
| Revenue (TTM) | €7.37m |
0.7x
P/S Ratio-0.9x
P/E RatioIs VCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VCC income statement (TTM) | |
|---|---|
| Revenue | US$8.01m |
| Cost of Revenue | US$3.18m |
| Gross Profit | US$4.82m |
| Other Expenses | US$10.52m |
| Earnings | -US$5.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | 60.25% |
| Net Profit Margin | -71.12% |
| Debt/Equity Ratio | 0% |
How did VCC perform over the long term?
See historical performance and comparison